Logo

JACS-UN

Jackson Acquisition Company II

JACS-UN

Jackson Acquisition Company II • NYSE
$10.74 ▲ 0.00% (+0.00)
Market Cap $314.21 M
52w High $11.95
52w Low $10.01
Dividend Yield 0%
P/E 0
Volume 201
Outstanding Shares 29.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $129.619K ▲ $2.346M ▲ 0% $0.08 ▲ $2.346M ▲
Q2-2025 $0 $129.037K ▼ $2.318M ▲ 0% $0.078 ▲ $-129.037K ▼
Q1-2025 $0 $206.321K ▲ $2.227M ▲ 0% $0.075 ▲ $2.227M ▲
Q4-2024 $0 $177.396K ▲ $381.082K ▲ 0% $0.04 ▲ $-177.396K ▼
Q3-2024 $0 $49.568K $-49.568K 0% $-0.002 $-49.568K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $585.116K ▼ $240.926M ▲ $240.602M ▲ $324.886K ▼
Q2-2025 $721.661K ▼ $238.635M ▲ $441.173K ▲ $238.194M ▲
Q1-2025 $755.968K ▼ $236.281M ▲ $405.164K ▲ $235.876M ▲
Q4-2024 $949.366K ▲ $234.006M ▲ $357.54K ▲ $233.648M ▲
Q3-2024 $0 $193.8K $218.368K $-24.568K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $2.346M ▲ $-136.545K ▼ $0 $0 $-136.545K ▼ $-136.545K ▼
Q2-2025 $2.318M ▲ $-34.307K ▲ $0 $0 $-34.307K ▲ $-34.307K ▲
Q1-2025 $2.227M ▲ $-193.398K ▲ $0 ▲ $0 ▼ $-193.398K ▼ $-193.398K ▲
Q4-2024 $381.082K $-302.833K $-232.3M $233.552M $949.366K $-302.833K

Five-Year Company Overview

Income Statement

Income Statement Jackson Acquisition Company II currently has no real operating business, so its income statement is essentially empty. There is no meaningful revenue, no cost of goods, and no typical operating profit or loss from a core activity. Any small earnings at this stage would mainly come from interest on the cash it raised, not from running a business. The financial story will only become relevant once a merger target is announced and combined financials are available.

Balance Sheet

Balance Sheet The balance sheet is typical for a newly listed SPAC: mostly cash raised from investors and essentially no operating assets. There is no debt reported, so the structure is very clean and simple, with equity funded almost entirely by the IPO proceeds. This means the company is financially light and flexible, but it also has no tangible operating business yet—its value is tied to the cash in trust and the team’s ability to deploy it. The main future risk is how efficiently and wisely that cash will be used when a merger is chosen.

Cash Flow

Cash Flow Cash flows at this point are minimal and largely reflect money raised and placed in trust, not business activity. There is no meaningful cash generation from operations because the company does not sell products or services. Cash outflows are mainly small corporate and administrative costs needed to keep the SPAC running. The real test of cash flow will only come after a merger, when the acquired business starts showing whether it can fund itself or needs ongoing support.

Competitive Edge

Competitive Edge As a SPAC, Jackson Acquisition Company II competes not through products, but through its ability to attract a strong healthcare company to merge with. Its main edge is its leadership team, which has deep experience and networks in healthcare services and technology, plus a well-known founder with a long track record in the sector. This reputation and network could help it source better-quality targets or negotiate more favorable terms than a less experienced sponsor. On the other hand, it faces competition from many other buyers—private equity, strategic acquirers, and other SPACs—also chasing attractive healthcare assets, and there is no guarantee it will secure a standout deal.

Innovation and R&D

Innovation and R&D The SPAC itself does not conduct research and development or create new products. Instead, its innovation story is entirely tied to the type of healthcare company it eventually acquires. Management has signaled a focus on healthcare services and technology, including areas like telehealth, software platforms, and data-driven care solutions, which could be fertile ground for innovation. Until a specific target is named, any view on innovation is speculative and depends largely on confidence in the team’s ability to identify and support a truly innovative healthcare business.

Summary

Jackson Acquisition Company II is essentially a pool of investor capital with an experienced healthcare-focused management team but no operating business yet. Its current financial statements are very simple: cash on the balance sheet, negligible operations, and no meaningful cash flow from business activity. The key strengths are a clean financial structure, a clear sector focus on healthcare services and technology, and a sponsor team with a long history in the industry. The main uncertainties are if and when it will find a suitable merger target, the quality and valuation of that target, and how successful the combined company will be once public. Any longer-term view depends almost entirely on the eventual acquisition, which has not yet been identified.